# A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

> **NCT00290706** · PHASE1,PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 32 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00290706
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04-07
- **Primary completion:** 2011-02-11
- **Final completion:** 2012-09-05
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Closed per Data Monitoring Committee due to lack of efficacy
- **Last updated:** 2019-05-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290706, "A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00290706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*